Shattuck Labs Secures $54.9M from Warrant Exercises, Reports Positive SL-325 Phase 1 Data, Extends Runway to 2029
STTK has more than doubled off its 52-week low of $0.712 on elevated volume (2.2× avg).
Summary
Shattuck Labs announced positive Phase 1 clinical trial results for its lead candidate SL-325 and secured $54.9 million from warrant exercises, extending its cash runway into 2029.
Key Events · Financing and Capital Events · STTK
-
Significant Capital Infusion from Warrant Exercises
The company received notices to exercise approximately 50.6 million common stock warrants, generating aggregate gross proceeds of $54.9 million. This represents a substantial capital raise for the company.
-
Extended Cash Runway into 2029
The proceeds from the warrant exercises, combined with existing cash and investments, are expected to fund operations into 2029, providing crucial financial stability for clinical development.
-
Positive Phase 1 Clinical Trial Results for SL-325
Shattuck Labs announced favorable Phase 1 data for SL-325, its lead DR3 blocking antibody, demonstrating a strong safety profile, durable blockade of TL1A binding, and a low immunogenicity rate (3.7% ADA).
-
Pipeline Advancement with Clear Milestones
The company plans to initiate a Phase 2b trial for SL-325 in Crohn's disease in Q3 2026 and expects to file an IND for its bispecific candidate SL-846 in the first half of 2027.
Analysis · STTK · Life Sciences
This 8-K delivers two significant positive updates for Shattuck Labs. The exercise of 50.6 million warrants, generating $54.9 million, provides a substantial capital infusion that significantly strengthens the balance sheet and extends the company's cash runway into 2029. This financial stability is critical for a clinical-stage biotechnology company. Concurrently, the positive Phase 1 clinical trial results for SL-325, demonstrating a favorable safety profile, durable DR3 blockade, and a low immunogenicity rate, de-risk the lead candidate and support its progression to a Phase 2b trial in Crohn's disease. The clear pipeline advancement, including the upcoming IND for SL-846, further enhances the company's long-term prospects.
At the time of this filing, STTK was trading at $4.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $327.4M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.